Similar articles for PMID: 30088682

Year	Number of Results
1992	1
1995	2
1996	3
1998	2
1999	4
2000	1
2002	1
2003	1
2005	3
2006	3
2007	2
2008	4
2009	4
2010	7
2011	8
2012	4
2013	3
2014	5
2015	12
2016	10
2017	6
2018	15
2019	10
2020	8
2021	8
2022	11
2023	1
2024	0

1

Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.

D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y. D'Antoni ML, et al. J Leukoc Biol. 2018 Dec;104(6):1241-1252. doi: 10.1002/JLB.5A0817-328RRR. Epub 2018 Aug 8. J Leukoc Biol. 2018. PMID: 30088682 Free PMC article.

2

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort. Visseaux B, et al. PLoS One. 2015 Aug 6;10(8):e0134904. doi: 10.1371/journal.pone.0134904. eCollection 2015. PLoS One. 2015. PMID: 26247470 Free PMC article.

3

Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.

DʼAntoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E, Seyedkazemi S, Nakamoto BK, Walker M, Kallianpur KJ, Ogata-Arakaki D, Ndhlovu LC, Shikuma C. DʼAntoni ML, et al. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):108-116. doi: 10.1097/QAI.0000000000001752. J Acquir Immune Defic Syndr. 2018. PMID: 29781885 Free PMC article. Clinical Trial.

4

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.

Bowler S, Siriwardhana C, Mitchell BI, D'Antoni ML, Ogata-Arakaki D, Souza S, Yee R, Gangcuangco LMA, Chow DC, Ndhlovu LC, Shikuma C. Bowler S, et al. HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):123-129. doi: 10.1080/25787489.2020.1719319. Epub 2020 Feb 4. HIV Res Clin Pract. 2019. PMID: 32013805 Clinical Trial.

5

Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.

Kwiatkowski K, Pawlik K, Ciapała K, Piotrowska A, Makuch W, Mika J. Kwiatkowski K, et al. Front Immunol. 2020 Dec 21;11:615327. doi: 10.3389/fimmu.2020.615327. eCollection 2020. Front Immunol. 2020. PMID: 33408720 Free PMC article.

6

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Kim MB, Giesler KE, Tahirovic YA, Truax VM, Liotta DC, Wilson LJ. Kim MB, et al. Expert Opin Investig Drugs. 2016 Dec;25(12):1377-1392. doi: 10.1080/13543784.2016.1254615. Expert Opin Investig Drugs. 2016. PMID: 27791451 Free PMC article. Review.

7

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA. Kramer VG, et al. J Antimicrob Chemother. 2015 Mar;70(3):750-6. doi: 10.1093/jac/dku451. Epub 2014 Nov 27. J Antimicrob Chemother. 2015. PMID: 25433008

8

Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.

Kwiatkowski K, Ciapała K, Rojewska E, Makuch W, Mika J. Kwiatkowski K, et al. Int Immunopharmacol. 2020 Jul;84:106540. doi: 10.1016/j.intimp.2020.106540. Epub 2020 May 11. Int Immunopharmacol. 2020. PMID: 32402949

9

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.

Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL. Lefebvre E, et al. PLoS One. 2016 Jun 27;11(6):e0158156. doi: 10.1371/journal.pone.0158156. eCollection 2016. PLoS One. 2016. PMID: 27347680 Free PMC article.

10

Mechanisms of CNS Viral Seeding by HIV⁺ CD14⁺ CD16⁺ Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders.

Veenstra M, León-Rivera R, Li M, Gama L, Clements JE, Berman JW. Veenstra M, et al. mBio. 2017 Oct 24;8(5):e01280-17. doi: 10.1128/mBio.01280-17. mBio. 2017. PMID: 29066542 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year